Hydroxyethyl starch 130/0.4

DRUG4 trials

Sponsors

Yonsei University, General Hospital of Ningxia Medical University, Xiangya Hospital of Central South University, Air Force Military Medical University, China

Conditions

Adverse EffectAnesthesia InductionHemodynamic StabilityHydroxyethyl StarchPatients Undergoing Cardiac Surgery With Cardiopulmonary BypassPerioperative Volume ReplacementTranscatheter Aortic Valve Replacement

Phase 4

Safety and Efficacy of Perioperative Volume Replacement with Volulyte 6% in Moderate-to-high Cardiovascular Risk Patients Having Major Abdominal Surgery

Not yet recruitingNCT06663254

Xiangya Hospital of Central South UniversityHydroxyethyl Starch, Perioperative Volume Replacement

Start: 2024-11-30End: 2026-08-30Target: 410Updated: 2024-10-29

Unknown Phase

A Comparison Between 5% Albumin and 6% Hydroxyethyl Starch 130/0.4 in Priming Solution for Cardiopulmonary Bypass and Post-bypass Maintenance Fluid in High-risk Patients

CompletedNCT01644084

Yonsei UniversityPatients Undergoing Cardiac Surgery With Cardiopulmonary Bypass

Start: 2009-06-30End: 2011-04-30Updated: 2012-07-19

6% Hydroxyethyl Starch (130/0.4) Coload for Postspinal Anesthesia Hypotension

RecruitingNCT05475886

General Hospital of Ningxia Medical UniversityAdverse Effect

Start: 2024-02-01End: 2024-04-21Target: 40Updated: 2024-02-02

Crystalloid vs Colloid for Hemodynamics During Anesthesia Induction in TAVR Patients

Not yet recruitingNCT07329660

Air Force Military Medical University, ChinaAnesthesia Induction, Hemodynamic Stability, Transcatheter Aortic Valve Replacement

Start: 2026-02-16End: 2026-12-31Target: 116Updated: 2026-02-27

Related Papers

Crystalloid vs colloid for Hemodynamics during Anesthesia INduction in TAVR patients (CHAIN-T): study protocol for a randomized controlled trial

Trials2026-07-24